Search
Partnering_In_INFECTIOUS_1
Partnering_In_Oncology_0422
Partnering_In_CARDIOMETABOLIC_0
Partnering_In_CENTRALNERVOUS_0
Partnering_In_Imm_0422
Partnering_In_ORALHEALTH_0
Partnering_In_PAIN_0
Partnering_In_TECHNOLOGIES_0
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory Diseases
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease Patients Around the World
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView”
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Awarded Top Employer In 29 Countries Including The Kingdom of Saudi Arabia
Boehringer Ingelheim Awarded Top Employer In 29 Countries Including The Kingdom of Saudi Arabia And The United Arab Emirates
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
“LastMile” – improving through digital
“LastMile” – improving through digital
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Winners of 2020 BVDzero Case Awards announced
Winners of 2020 BVDzero Case Awards announced